An analysis examining Medicare data found that the number of elderly beneficiaries receiving narcotic painkillers and anti-anxiety medications drastically increased from 2007 to 2012.
An analysis examining Medicare data found that the number of elderly beneficiaries receiving narcotic painkillers and anti-anxiety medications drastically increased from 2007 to 2012. Those patients were also found to be taking medications for much longer periods of time than other patients.
To be exact, 8.5 million patients aged 65 years and older received prescriptions under Medicare for opioid pain medications—a 30% increase over 5 years. As well, the use of drugs like hydrocodone and oxycodone grew more than 50%, while the amount of each narcotic provided to the average beneficiary rose 15% to about 3 months’ supply. The data suggests that nearly 1 in 5 Medicare beneficiaries is using the drugs for pain management on a long-term basis.
“The big surprise for me is the amount of time that people are being left on these drugs—it’s really concerning,” said Linda Simoni-Wastila, BSPharm, PhD, professor at the University of Maryland School of Pharmacy.
The number of senior patients who were prescribed anti-anxiety medications, including alprazolam and buspirone, also rose by 25% to 700,000 beneficiaries. They received an average of 5 months’ supply of the medications in 2012—a 10% increase from 2007.
The statistics are concerning for public health officials, as the long-term use of pain and antianxiety medications can put patients at risk for abuse or dependence.
Officials from CMS said, “Medicare takes instances of prescription drug misuse very seriously and recently put in place aggressive new rules that take further steps to prevent drug abuse and overutilization.”
Around the Web
Seniors' Use of Potent Meds via Medicare Staggering [USA Today]
Review Emphasizes Potential Infection Risks With BTK Inhibitors
November 2nd 2024Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
PAH Treatment Outcomes Similar Regardless of Diagnosis Time
November 1st 2024The study findings underscore the importance of early initiation of macitentan and tadalafil among patients who have pulmonary arterial hypertension (PAH), and represent a shift in understanding of prognosis based on diagnosis timing.
Read More